{"url_path":"/sec/siga/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 ** **Exhibits and Financial Statement Schedules**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-10","source_url":"https://www.sec.gov/Archives/edgar/data/1010086/0001437749-26-007557-index.html","accession_number":"0001437749-26-007557","cik":"0001010086","ticker":"SIGA","issuer_name":"SIGA TECHNOLOGIES INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1010086/0001437749-26-007557-index.html","primary_entity_key":"0001010086","primary_entity_name":"SIGA TECHNOLOGIES INC"},"word_count":3183,"has_tables":true,"body_markdown":"** **\n\n**Item 15.** **Exhibits and Financial Statement Schedules**\n\n \n\n**(a) (1) and (2). Financial Statements.**\n\n \n\nSee Index to Financial Statements under Item 8 in Part II hereof where these documents are listed. All schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.\n\n \n\n**(a) (3). Exhibits.**\n\n \n\nThe following is a list of exhibits:\n\n \n\nExhibit\n\nNo.\n\nDescription\n\n[3(a)](ex_925381.htm)\n\nAmended and Restated Certificate of Incorporation of SIGA Technologies, Inc.\n\n \n\n \n \n \n\n[3(b)](http://www.sec.gov/Archives/edgar/data/1010086/000114036125022316/ef20050546_ex3-1.htm)\nAmended and Restated By-laws of SIGA Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company filed on June 12, 2025).\n \n\n \n \n \n\n[4(a)](http://www.sec.gov/Archives/edgar/data/1010086/0000950130-97-000939.txt)\n\nForm of Common Stock Certificate (incorporated by reference to the Form SB-2 Registration Statement of the Company dated March 10, 1997 (No. 333-23037)).\n\n \n\n \n \n \n\n[4(b)](http://www.sec.gov/Archives/edgar/data/1010086/000101008620000006/a4b-description_ofxsecurit.htm)\n\nDescription of the Registrant's Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4(b) to the Annual Report on Form 10-K of the Company filed on March 5, 2020).\n\n \n\n \n \n \n\n[10(a)](http://www.sec.gov/Archives/edgar/data/1010086/000092242303000954/kl08031_ex10-fff.txt)\nSecurities Purchase Agreement, dated as of August 13, 2003, between the Company and MacAndrews & Forbes Holdings Inc. (incorporated by reference to Exhibit 10(fff) to the Current Report on Form 8-K of the Company filed on August 18, 2003).\n \n\n \n \n \n\n[10(b)](http://www.sec.gov/Archives/edgar/data/1010086/000114036121014598/nc10021482x1_def14a.htm)\n\nDirector Compensation Program, effective April 8, 2021 (incorporated by reference to the Definitive Proxy Statement on Form DEF 14A of the Company filed on April 27, 2021).*\n\n \n\n \n\n[10(c)](http://www.sec.gov/Archives/edgar/data/1010086/000114036116061132/ex10_2.htm)\n\nAmended and Restated Employment Agreement, dated April 12, 2016, between SIGA Technologies, Inc. and Daniel J. Luckshire (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on April 14, 2016).*\n\n \n\n \n\n[10(d)](http://www.sec.gov/Archives/edgar/data/1010086/000114036116061132/ex10_3.htm)\n\nAmended and Restated Employment Agreement, dated April 12, 2016, between SIGA Technologies, Inc. and Dennis E. Hruby (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K of the Company filed on April 14, 2016).*\n\n \n\n \n\n[10(e)](http://www.sec.gov/Archives/edgar/data/1010086/000114036117022812/ex10_1.htm)\n\nOffice Lease, dated as of May 26, 2017, by and between SIGA Technologies, Inc. and MacAndrews & Forbes Incorporated (portions of this exhibit have been omitted and separately filed with the Securities and Exchange Commission with a request for confidential treatment) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on May 30, 2017).\n\n \n\n \n \n \n\n[10(f)](http://www.sec.gov/Archives/edgar/data/1010086/000101008617000012/siga-exhibit102leaseaggrem.htm)\n\nCommercial Lease Agreement for Corvallis, Oregon dated November 3, 2017 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed on November 7, 2017).\n\n \n\n \n\n[10(g)](http://www.sec.gov/Archives/edgar/data/1010086/000114036118036170/ex10_1.htm)\n\nAddendum, dated August 10, 2018, to Second Amended and Restated Employment Agreement, dated April 12, 2016, between SIGA Technologies, Inc. and Dennis E. Hruby (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on August 10, 2018).*\n\n \n\n \n \n \n\n[10(h)](http://www.sec.gov/Archives/edgar/data/1010086/000114036118038195/ex10_1.htm)\n\nContract, dated as of September 10, 2018, between SIGA Technologies, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted and separately filed with the Securities and Exchange Commission with a request for confidential treatment) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on September 11, 2018).\n\n \n\n \n \n \n\n[10(i)](http://www.sec.gov/Archives/edgar/data/1010086/000101008619000007/albemarlecmoagreement.htm)\n\nCommercial Manufacturing Agreement, dated October 1, 2018, by and between Albemarle Corporation and SIGA (portions of this exhibit have been omitted and separately filed with the Securities and Exchange Commission with a request for confidential treatment) (incorporated by reference to Exhibit 10.2 to the Annual Report on Form 10-K of the Company filed on March 6, 2019).\n\n \n\n \n \n \n\n[10(j)](http://www.sec.gov/Archives/edgar/data/1010086/000101008619000007/barda2018-mod1.htm)\n\nAmendment of Solicitation/Modification of Contract 0001, dated February 21, 2019, to Agreement, dated September 10, 2018, between the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services and SIGA (incorporated by reference to Exhibit 10.1 to the Annual Report on Form 10-K of the Company filed on March 6, 2019).\n\n \n\n \n\n73\n\n[Table of Contents](#toc)\n\n \n\n[10(k)](http://www.sec.gov/Archives/edgar/data/1010086/000114036119009448/ex10_1.htm)\n\nAmendment of Solicitation/Modification of Contract 0002, dated May 17, 2019, to Agreement, dated September 10, 2018 by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on May 20, 2019).\n\n \n\n \n \n \n\n[10(l)](http://www.sec.gov/Archives/edgar/data/1010086/000114036119010237/ex10_1.htm)\n\nPromotion Agreement, dated May 31, 2019, by and between SIGA Technologies, Inc. and Meridian Medical Technologies, Inc. (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on June 3, 2019).\n\n \n\n \n \n \n\n[10(m)](http://www.sec.gov/Archives/edgar/data/1010086/000101008619000018/exhibit101-mod0003redacted.htm)\n\nAmendment of Solicitation/Modification of Contract 0003, dated September 9, 2019, to Agreement, dated September 10, 2018 by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on November 5, 2019).\n\n \n\n \n \n \n\n[10(n)](http://www.sec.gov/Archives/edgar/data/1010086/000143774920009619/ex_184040.htm)\nAmendment of Solicitation/Modification of Contract 0004, dated February 4, 2020, to Agreement, dated September 10, 2018 by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on May 6, 2020).\n \n\n \n \n \n\n[10(o)](http://www.sec.gov/Archives/edgar/data/1010086/000143774920016895/ex_194496.htm)\nAmendment of Solicitation/Modification of Contract 0005, dated April 29, 2020, to Agreement, dated September 10, 2018 by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on August 6, 2020).\n \n\n \n \n \n\n[10(p)](http://www.sec.gov/Archives/edgar/data/1010086/000143774921025323/ex_284769.htm)\nAmendment of Solicitation/Modification of Contract 0007, dated September 8, 2021, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on November 4, 2021).\n \n\n \n \n \n\n[10(q)](http://www.sec.gov/Archives/edgar/data/1010086/000143774922005179/ex_333999.htm)\nAmendment of Solicitation/Modification of Contract 00006, dated April 29, 2021, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10(tt) to the Annual Report on Form 10-K of the Company filed on March 3, 2022).\n \n\n \n \n \n\n[10(r)](http://www.sec.gov/Archives/edgar/data/1010086/000143774922005179/ex_334000.htm)\nAmendment of Solicitation/Modification of Contract 00008, dated December 9, 2021, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (incorporated by reference to Exhibit 10(uu) to the Annual Report on Form 10-K of the Company filed on March 3, 2022).\n \n\n \n \n \n\n[10(s)](http://www.sec.gov/Archives/edgar/data/1010086/000143774922025799/ex_433922.htm)\nAmendment of Solicitation/Modification of Contract 00009, dated January 27, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on November 3, 2022).\n \n\n \n \n \n\n[10(t)](http://www.sec.gov/Archives/edgar/data/1010086/000143774922025799/ex_433923.htm)\nAmendment of Solicitation/Modification of Contract 00010, dated March 29, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed on November 3, 2022).\n \n\n \n \n \n\n74\n\n[Table of Contents](#toc)\n\n \n \n \n\n[10(u)](http://www.sec.gov/Archives/edgar/data/1010086/000143774922025799/ex_430842.htm)\nAmendment of Solicitation/Modification of Contract 000011, dated July 26, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of the Company filed on November 3, 2022).\n \n\n \n \n \n\n[10(v)](http://www.sec.gov/Archives/edgar/data/1010086/000143774922025799/ex_420884.htm)\nAmendment of Solicitation/Modification of Contract 000012, dated August 5, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K) (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of the Company filed on November 3, 2022).\n \n\n \n \n \n\n[10(w)](http://www.sec.gov/Archives/edgar/data/1010086/000143774923022546/ex_532471.htm)\nProposal for the Amendment of the Employment Agreement with Dennis E. Hruby (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on August 8, 2023).* \n \n\n \n \n \n\n[10(x)](http://www.sec.gov/Archives/edgar/data/1010086/000143774923022546/ex_549929.htm)\nAmendment of Solicitation/Modification of Contract 00013, dated July 27, 2023, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed on August 8, 2023).\n \n\n \n \n \n\n[10(y)](http://www.sec.gov/Archives/edgar/data/1010086/000114036124003106/ef20019267_ex10-1.htm)\nEmployment Agreement, dated January 19, 2024, between SIGA Technologies, Inc. and Diem Nguyen (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed January 22, 2024).*\n \n\n \n \n \n\n[10(z)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924007487/ex_598879.htm)\nAmendment of Solicitation/Modification of Contract 00014, dated October 18, 2023, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10(mmm) to the Annual Report on Form 10-K of the Company filed on March 12, 2024).\n \n\n \n \n \n\n[10(aa)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924007487/ex_625610.htm)\nAmendment of Solicitation/Modification of Contract 00015, dated February 9, 2024, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10(nnn) to the Annual Report on Form 10-K of the Company filed on March 12, 2024).\n \n\n \n \n \n\n[10(bb)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924015124/ex_654007.htm)\nEmployment Agreement, dated February 26, 2024, between SIGA Technologies, Inc. and Larry Miller (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed on May 7, 2024).*\n \n\n \n \n \n\n[10(cc)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924015124/ex_660603.htm)\nAmendment No. 1 to Promotion Agreement, dated September 10, 2020, between SIGA Technologies, Inc. and Meridian Medical Technologies, Inc. (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of the Company filed on May 7, 2024).\n \n\n \n \n \n\n[10(dd)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924015124/ex_654662.htm)\nLetter Amendment to Promotion Agreement, dated February 28, 2024, between SIGA Technologies, Inc. and Meridian Medical Technologies, LLC  (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of the Company filed on May 7, 2024).\n \n\n \n \n \n\n[10(ee)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924015124/ex_654661.htm)\nLetter Amendment to Promotion Agreement, dated March 26, 2024, between SIGA Technologies, Inc. and Meridian Medical Technologies, LLC (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q of the Company filed on May 7, 2024).\n \n\n \n \n \n\n[10(ff)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924015124/ex_654663.htm)\nAmendment No. 2 to Promotion Agreement, dated March 27, 2024, between SIGA Technologies, Inc. and Meridian Medical Technologies, LLC (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q of the Company filed on May 7, 2024).\n \n\n \n \n \n\n[10(gg)](http://www.sec.gov/Archives/edgar/data/1010086/000143774925007056/ex_778098.htm)\nSIGA Technologies, Inc. 2010 Stock Incentive Plan (amended and restated effective May 23, 2017) (incorporated by reference to Exhibit 10(nn) to the Annual Report on Form 10-K of the Company filed on March 11, 2025).\n \n\n \n \n \n\n[10(hh)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924024320/ex_699598.htm)\nForm of Stock Option Grant Agreement under the SIGA Technologies, Inc. 2010 Stock Incentive Plan (amended and restated effective May 23, 2017) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on August 1, 2024).*\n \n\n \n \n \n\n75\n\n[Table of Contents](#toc)\n\n \n \n \n\n[10(ii)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924024320/ex_699599.htm)\nForm of Restricted Stock Unit Grant Agreement under the SIGA Technologies, Inc. 2010 Stock Incentive Plan (amended and restated effective May 23, 2017) (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed on August 1, 2024).*\n \n\n \n \n \n\n[10(jj)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924024320/ex_699600.htm)\nForm of Performance Stock Unit Grant Agreement under the SIGA Technologies, Inc. 2010 Stock Incentive Plan (amended and restated effective May 23, 2017) (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of the Company filed on August 1, 2024).*\n \n\n \n \n \n\n[10(kk)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924024320/ex_699601.htm)\nForm of Non-Employee Directors Restricted Stock Unit Grant Agreement under the SIGA Technologies, Inc. 2010 Stock Incentive Plan (amended and restated effective May 23, 2017) (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of the Company filed on August 1, 2024).*\n \n\n \n \n \n\n[10(ll)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924024320/ex_699602.htm)\nForm of Indemnification Agreement for Directors and Officers (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q of the Company filed on August 1, 2024).\n \n\n \n \n \n\n[10(mm)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924024320/ex_703019.htm)\nAmendment of Solicitation/Modification of Contract 00016, dated July 18, 2024, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q of the Company filed on August 1, 2024).\n \n\n \n \n \n\n[10(nn)](http://www.sec.gov/Archives/edgar/data/1010086/000114036124042883/ef20036718_ex10-1.htm)\nAmendment to Amended and Restated Employment Agreement between SIGA Technologies, Inc. and Daniel J. Luckshire, dated as of October 1, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on October 4, 2024).*\n \n\n \n \n \n\n[10(oo)](http://www.sec.gov/Archives/edgar/data/1010086/000114036124042883/ef20036718_ex10-2.htm)\nSecond Amendment to Third Amended and Restated Employment Agreement between SIGA Technologies, Inc. and Dennis E. Hruby, dated as of October 1, 2024 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on October 4, 2024).*\n \n\n \n \n \n\n[10(pp)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924033966/ex_734039.htm)\nConsulting Agreement, dated October 19, 2020, between SIGA Technologies, Inc. and Tides Group, LLC  (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of the Company filed on November 7, 2024).\n \n\n \n \n \n\n[10(qq)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924033966/ex_734040.htm)\nAmendment #1, dated September 1, 2022, to the Consulting Agreement, dated October 19, 2020, between SIGA Technologies, Inc. and Tides Group, LLC (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of the Company filed on November 7, 2024).\n \n\n \n \n \n\n[10(rr)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924033966/ex_734041.htm)\nStatement of Work #1, dated October 19, 2020, between SIGA Technologies, Inc. and Tides Group, LLC (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q of the Company filed on November 7, 2024).\n \n\n \n \n \n\n[10(ss)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924033966/ex_734042.htm)\nAmendment #1, dated September 26, 2024, to Statement of Work #1, dated October 19, 2020, between SIGA Technologies, Inc. and Tides Group, LLC (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q of the Company filed on November 7, 2024).\n \n\n \n \n \n\n[10(tt)](http://www.sec.gov/Archives/edgar/data/1010086/000143774924033966/ex_734043.htm)\nAmendment, dated August 30, 2024, to Promotion Agreement, dated May 31, 2019, by and between SIGA Technologies, Inc. and Meridian Medical Technologies, Inc. (incorporated by reference to Exhibit 10.7 to the Quarterly Report on Form 10-Q of the Company filed on November 7, 2024).\n \n\n \n \n \n\n76\n\n[Table of Contents](#toc)\n\n \n \n \n\n[10(uu)](http://www.sec.gov/Archives/edgar/data/1010086/000143774925015542/ex_807285.htm)\nAmendment of Solicitation/Modification of Contract 00017, dated March 26, 2025, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on May 8, 2025).\n \n\n \n \n \n\n[10(vv)](http://www.sec.gov/Archives/edgar/data/1010086/000143774925015542/ex_807286.htm)\nAmendment of Solicitation/Modification of Contract 00018, dated April 8, 2025, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed on May 8, 2025).\n \n\n \n \n \n\n[10(ww)](http://www.sec.gov/Archives/edgar/data/1010086/000143774925024889/ex_828784.htm)\nAmendment of Solicitation/Modification of Contract 00019, dated June 3, 2025, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company filed on August 5, 2025).\n \n\n \n \n \n\n[19.1](http://www.sec.gov/Archives/edgar/data/1010086/000143774925007056/ex_777066.htm)\nSIGA Technologies, Inc. Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the Annual Report on Form 10-K of the Company filed on March 11, 2025).\n \n\n \n \n \n\n[23.1](ex_867258.htm)\n\nConsent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.\n\n \n\n \n \n \n\n[31.1](ex_867259.htm)\n\nCertification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002-Chief Executive Officer.\n\n \n\n \n \n \n\n[31.2](ex_867260.htm)\n\nCertification pursuant to Rules 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002-Chief Financial Officer.\n\n \n\n \n \n \n\n[32.1](ex_867261.htm)\n\nCertification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002-Chief Executive Officer.\n\n \n\n \n \n \n\n[32.2](ex_867262.htm)\n\nCertification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002-Chief Financial Officer.\n\n \n\n \n \n \n\n[97.1](http://www.sec.gov/Archives/edgar/data/1010086/000143774924007487/ex_598878.htm)\nSIGA Technologies, Inc. Clawback Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K of the Company filed March 12, 2024).\n \n\n \n\n101.INS\n\nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)\n\n \n\n \n \n \n\n101.SCH\n\nInline Taxonomy Extension Schema Document\n\n \n\n \n \n \n\n101.CAL\n\nInline Taxonomy Extension Calculation Linkbase Document\n\n \n\n \n \n \n\n101.DEF\n\nInline Taxonomy Extension Definition Linkbase Document\n\n \n\n \n \n \n\n101.LAB\n\nInline Taxonomy Extension Labels Linkbase Document\n\n \n\n \n \n \n\n101.PRE\n\nInline Taxonomy Extension Presentation Linkbase Document\n\n \n\n \n \n \n\n104\nCover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)\n \n\n \n\n* Management contract, compensatory plan or arrangement.\n\n \n\n77\n\n[Table of Contents](#toc)"}